Compare Globus Medical Inc. Class A Common Stock (GMED) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs SPDR Kensho Final Frontiers ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while SPDR Kensho Final Frontiers ETF trades at $100.25 (market cap $165.02M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 62.1× SPDR Kensho Final Frontiers ETF's market cap, and SPDR Kensho Final Frontiers ETF is more actively traded (15,155 versus 1,059,528). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and SPDR Kensho Final Frontiers ETF for 14 Days on average.
| GMED | ROKT | |
|---|---|---|
Market Cap | $10.25B | $165.02M |
Volume | 1,059,528 | 15,155 |
Sector | Health | Sector/Thematic |
52-Week High | $96.82 | $136.68 |
52-Week Low | $58.33 | $72.93 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ROKT (SPDR S&P Kensho Final Frontiers ETF) trades at $101.88, down 1.0% today, with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The ETF provides diversified exposure to aerospace and defense companies, though key financial ratios are currently unavailable. Recent news highlights growing investor interest in space-related investments through diversified vehicles like ROKT rather than individual space stocks.
The ETF offers efficient exposure to the final frontiers theme but faces challenges from high operational costs and profitability timelines in the space sector. Current bearish technical indicators suggest near-term pressure, while long-term growth potential in aerospace and defense remains supported by industry developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
